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Abstract 
Background: Vascular stiffening, a risk factor for cardiovascular disease, is accelerated, particularly in women with 
obesity and type 2 diabetes. Preclinical evidence suggests that dipeptidylpeptidase‑4 (DPP‑4) inhibitors may have 
cardiovascular benefits independent of glycemic lowering effects. Recent studies show that consumption of a west‑
ern diet (WD) high in fat and simple sugars induces aortic stiffening in female C57BL/6J mice in advance of increasing 
blood pressure. The aims of this study were to determine whether administration of the DPP‑4 inhibitor, linagliptin 
(LGT), prevents the development of aortic and endothelial stiffness induced by a WD in female mice.
Methods: C56Bl6/J female mice were fed a WD for 4 months. Aortic stiffness and ex vivo endothelial stiffness were 
evaluated by Doppler pulse wave velocity (PWV) and atomic force microscopy (AFM), respectively. In addition, we 
examined aortic vasomotor responses and remodeling markers via immunohistochemistry. Results were analyzed via 
2‑way ANOVA, p < 0.05 was considered as statistically significant.
Results: Compared to mice fed a control diet (CD), WD‑fed mice exhibited a 24 % increase in aortic PWV, a five‑fold 
increase in aortic endothelial stiffness, and impaired endothelium‑dependent vasodilation. In aorta, these findings 
were accompanied by medial wall thickening, adventitial fibrosis, increased fibroblast growth factor 23 (FGF‑23), 
decreased Klotho, enhanced oxidative stress, and endothelial cell ultrastructural changes, all of which were prevented 
with administration of LGT.
Conclusions: The present findings support the notion that DPP‑4 plays a role in development of WD‑induced aortic 
stiffening, vascular oxidative stress, endothelial dysfunction, and vascular remodeling. Whether, DPP‑4 inhibition could 
be a therapeutic tool used to prevent the development of aortic stiffening and the associated cardiovascular compli‑
cations in obese and diabetic females remains to be elucidated.
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Background
Increased arterial stiffness is a cardiovascular (CV) bio-
marker strongly associated with hypertension, diastolic 
heart failure, chronic kidney disease and stroke [1, 2]. 
Importantly, obese, insulin resistant and diabetic women 
develop vascular stiffness more frequently than men and 
this circumstance might account for the disproportion-
ate incidence of cardiovascular disease (CVD) in insulin 
resistant women [3, 4]. The widespread consumption of 
diets high in refined carbohydrates and fat [western diet 
(WD)] is one of the driving forces behind the alarming 
growth in the incidence of obesity and insulin resistance 
[5, 6]. The progression to CVD in the setting of obe-
sity and type 2 diabetes is likely initiated by endothelial 
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dysfunction and several associated vascular abnormali-
ties, including altered vascular tone, extracellular matrix 
remodeling and adventitial dysfunction, all of which 
could promote arterial stiffness [7, 8]. We recently tested 
this notion and reported that after 4 months of WD feed-
ing, the aorta of normotensive female C57BL/6J mice 
exhibits altered nitric oxide (NO)-dependent vasodi-
lation associated with aortic and endothelial stiffness, 
increased aortic wall thickening and fibrosis, oxidative 
stress and inflammation [9]. Recent reports from our 
laboratory indicate that therapies targeting vascular stiff-
ness could potentially improve CV outcomes in insulin 
resistance models [7, 9]. In this regard, the use of dipep-
tidyl peptidase-4 (DPP-4) inhibitors may be of interest. 
DPP-4 is an exopeptidase that circulates in plasma and 
is also expressed on the surface of multiple cell types 
including endothelial and vascular smooth muscle cells, 
as well as immune cells [10]. Although DPP-4 inhibitors 
were developed to control hyperglycemia, it is now estab-
lished that these inhibitors have effects beyond glycemic 
regulation [11]. The rationale for using DPP-4 inhibi-
tors to target vascular stiffness relates to the potential of 
these compounds to improve endothelial function [11, 
12]. Even though the beneficial effects of DPP-4 inhibi-
tion on the cardiovascular system have been explored in 
both animal models and in type 2 diabetic patients [11], 
to the best of our knowledge, the potential role of these 
compounds to target vascular stiffness in a female rodent 
model of insulin resistance due to over-nutrition with-
out frank hyperglycemia or blood pressure elevation has 
not been studied. In the present investigation, we tested 
whether administering linagliptin (LGT), a long acting 
and specific DPP-4 inhibitor, to female C57BL/6  J mice 
fed a WD for 4  months, could ameliorate the develop-
ment of WD-induced aortic and endothelial cell (EC) 
stiffness. Herein, we report that DPP-4 inhibition pre-
vents the development of WD-induced aortic and EC 
stiffness in overweight female mice. The mechanism, in 
part, appears a consequence of preventing abnormalities 
in aortic endothelium-dependent vasorelaxation, oxida-
tive stress, medial wall thickening and fibrosis, as well as 
expression of FGF-23 and Klotho.
Methods
Animal models
Three week old C57BL/6  J female mice were purchased 
from Jackson Laboratories (Bar Harbor, ME) and cared 
for in accordance with National Institutes of Health 
guidelines. All procedures were approved in advance 
by the Institutional Animal Care and Use Committee of 
the University of Missouri. Beginning at 4 weeks of age, 
mice were fed a WD consisting of high fat (46  %) and 
high carbohydrate as sucrose (17.5 %) and high fructose 
corn syrup (17.5  %) for 4  months (Test Diet 58Y1 with 
high refined carbohydrate and high fat, 5APC, Rich-
mond, Indiana). Parallel groups of age-matched control 
mice were fed a modified control diet (CD) for the same 
period of time (Test Diet 58Y2). Mice were provided 
water ad  libitum while housed in groups of four under 
a 12-hour/day illumination regimen. Based on a daily 
food intake of 0.1 g of chow per g body weight observed 
in a previous cohort of WD-fed mice, we added LGT (BI 
1356; (R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-me-
thyl-1-(4-methyl-quinazolin2-ylmethyl)-3,7-dihydro-
purine-2,6-dione) [13] to mouse chow so that the final 
concentration in chow was 83 mg LGT kg−1 to achieve a 
dose and plasma level of approximately 8 mg kg−1 day−1 
and approximately 50–100  nM, respectively [14]. Four 
groups of mice were utilized and they include mice fed a 
control diet without LGT (CDC), control diet with LGT 
(CDL), western diet without LGT (WDC) and western 
diet with LGT (WDL). Different sub-cohorts underwent 
the procedures described below.
Body weight
To assess weight gained during the 4 month experiment, 
mice were weighed immediately prior to the start of the 
experiment at 4 weeks of age and before sacrifice.
DPP‑4 activity assay
DPP-4 activity assay was performed as previously 
described [15]. Briefly, blood was collected at the time of 
killing in EDTA tubes and plasma was stored at −80 °C. 
20  μL plasma was diluted in DPP-4 assay buffer and 
substrate, 200  M H-Ala-Pro-AFC (I-1680; Bachem), 
was added. Fluorescence was measured with a Synergy 
Microplate Reader at excitation wavelength of 405  nm 
and emission wavelength of 535 nm [15].
Aortic stiffness by in vivo pulse wave velocity (PWV)
Doppler ultrasound (Indus Mouse Doppler System, 
Webster, TX) was performed under isoflurane anesthe-
sia, according to a previously established protocol [9], to 
evaluate PWV for in vivo determination of arterial stiff-
ness. PWV is affected by age, blood pressure, and heart 
rate. Consequently, PWV is reported both in m/s (unad-
justed), as well as normalized to heart rate (HR). Limiting 
the WD feeding period to 4 months allowed us to avoid 
any effects of increased blood pressure on vascular stiff-
ening as 4 months of WD does not induce an elevation of 
blood pressure in female C57BL/6J mice [9].
Ex vivo vasomotor responses in the aorta
Aortic vasomotor responses were examined as previously 
described [9]. Briefly, vessels were preconstricted with 
U46619 (100 nM) and responses to acetylcholine (ACh) 
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(1  nm to 100  μmM), and to insulin (INS: Novolin R, 
Novo Nordisk; 0.1–300 ng/mL) were assessed by cumula-
tive addition of agonist to an isolated vessel bath as previ-
ously described [9]. At the end of each experiment, the 
PSS bath solution was replaced with Ca2+-free PSS to 
determine maximal relaxation.
Atomic force microscopy (AFM) for force measurement 
and stiffness calculation
AFM was used to evaluate stiffness of ECs in enface 
aortic preparations of the thoracic aorta as previously 
described [9]. Stiffness (elastic modulus) of the EC sur-
face was measured by AFM using a nano-indentation 
protocol [9].
Aortic remodeling and protein quantification
A segment of thoracic aorta was fixed in 3 % paraformal-
dehyde, dehydrated, paraffin embedded, and transversely 
sectioned in 5  µm slices. To evaluate peri-aortic fibro-
sis, as previously described, the sections were stained 
with picro sirius red. To evaluate the medial thickness 
the sections were stained with Verhoeff-von Gieson [9]. 
The pink color intensities and areas were quantified as 
“average gray scale intensities” in five images per mouse 
with MetaVue software. Aortic oxidative stress was 
assessed by quantifying brown color in the endothelium, 
media and adventitia of the aorta which is indicative of 
3-nitrotyrosine formation (1:150 dilution; Millipore, 
Billerica, MA), as previously described [16]. The expres-
sion level of fibroblast growth factor-23 (FGF-23) (1:50 
dilution; Novus NBP1-55830), klotho (1:100 dilution; 
Novus  NBP1-76511) and advanced glycation end-
products (AGE) (1:100 dilution; Abcam ab23722) was 
determined by quantifying of signal intensities on the 
fluorescent images on the different components of aorta 
as “average gray scale intensities”.
Transmission electron microscopy (TEM)
TEM was performed as previously described using 
a JEOL 1400-EX TEM to determine ultrastructural 
changes associated with increased vascular stiffness [17]. 
Briefly, aortic samples were collected and fixed in 2  % 
glutaraldehyde/2  % paraformaldehyde followed by sec-
ondary fixation with 1 % osmium tetroxide, embedded in 
Epon-Spurr’s resin, sectioned at 85 nm, and stained with 
uranyl acetate/Sato’s triple lead stain.
Statistical analysis
Results are reported as the mean ± SE. Statistical analy-
sis was primarily by two-way ANOVA followed by post 
hoc t tests (Bonferroni) to examine differences in out-
comes between mice fed CD or WD and administered 
LGT in mouse chow or with no LGT in the chow (Sigma 
Plot 13.0, Systat Software). Aortic dilator responses are 
presented as percent maximal relaxation, calculated as 
[(Fb−Fd)/(Fb−Fmin)]*100, where Fd is force after a drug 
intervention, Fb is baseline force, and Fmin is minimal 
force obtained during passive conditions.
Results
Body weight, plasma DPP‑4 activity and AGE
Body weights of 20-week old WDC and WDL mice were 
of similar weights and heavier compared to those of their 
respective lean counterparts (Additional file 1: Table S1; 
Fig.  1a). Percent body weight gain during the 4  month 
study period was 71  ±  4 and 93  ±  6  % for CDC and 
WDC (p > 0.05), respectively, and 74 ± 7 % and 88 ± 7 % 
for CDL and WDL (p > 0.05), respectively. Thus, DPP-4 
inhibition had no significant effect on body weight (Addi-
tional file 1: Table S1; Fig. 1a) within each dietary regime 
during the test period. As expected, DPP-4 plasma activ-
ity was significantly decreased in both groups treated 
with LGT without a diet effect (Fig.  1b). As AGE have 
been associated with vascular stiffness in some mod-
els of insulin resistance [18, 19], we examined the pres-
ence of AGE in the aortic wall (Fig. 1c). WD significantly 
increased the accumulation of AGE in the vascular wall, 
and this was not affected by administration of LGT.
DPP‑4 inhibition prevented WD‑induced aortic and EC 
stiffness
In vivo
PWV was determined in mice following four months on 
CD or WD (Fig.  2a). PWV did not vary significantly in 
CDC mice (Fig.  2a; Table  1). PWV was elevated in the 
WDC group compared to CDC (p  <  0.001) and admin-
istration of LGT prevented the WD-induced increase 
in PWV (p < 0.001) (Fig. 2a; Table 1). No differences in 
PWV were observed between CDL and WDL groups 
(p = 0.363). Normalization of PWV to HR yielded similar 
results as shown in the adjusted PWV analysis (Table 1).
Ex vivo
We recently reported increased EC stiffness in aortic 
explants utilizing AFM after 4 months of WD in female 
mice [9]. Similarly, in this investigation we observed 
increased surface stiffness in the EC from WD-fed mice 
(p < 0.05 CDC vs. WDC) and this finding was prevented 
by LGT administration (p < 0.05 for WDC vs. WDL and 
p > 0.05 for CDC vs. WDL) (Fig. 2b).
DPP‑4 inhibition improves endothelial dependent 
responses in the aorta
We recently reported that 4  months of WD feeding 
in female C57BL/6J mice induced impaired protein 
kinase B (Akt)/endothelial nitric oxide synthase (eNOS) 
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signaling and this was associated with impaired aortic 
endothelium-dependent vasodilation [9]. Herein, we 
evaluate Akt/eNOS signaling in aortic rings by func-
tional assay to examine the vasodilatory responses to 
ACh and insulin. Four months of WD feeding resulted 
in impaired aortic endothelium-dependent vasodilatory 
responses to ACh and insulin in the WDC compared to 
CDC (Fig.  3a, b). These defects were prevented in the 
WDL group (Fig. 3a, b).
DPP‑4 inhibition prevents vascular remodeling
We have previously shown that WD feeding results 
in increased aortic remodeling. Similarly, in the pre-
sent investigation, aortic medial thickness and fibrosis 
were significantly increased with WD feeding compared 
to CDC (Fig.  4a–d). Importantly, aortic fibrosis and 
increased medial thickness were prevented with DPP-4 
inhibition (Fig. 4a–d).
DPP‑4 inhibition prevents the increase in WD‑induced 
ultrastructure changes in EC
Increased activation of the contractile apparatus of EC 
has been associated with the genesis of vascular stiff-
ness [20]. In this study, we examined the ultrastructural 
characteristics of the aorta in the different experimental 
groups (Fig. 5a–d). WD was associated with loss of lumi-
nal endothelial cytoplasmic elongation and nuclear con-
traction and these abnormalities were prevented in the 
WDL group (Fig. 5c, d).
DPP‑4 inhibition prevents oxidative stress
We have previously shown that vascular stiffness induced 
by WD feeding in females was associated with increased 
vascular oxidative stress [9]. Here in we showed that WD 
increased aortic oxidative stress assessed by the presence 
of 3-nitrotyrosine immunostaining (Fig. 6). Importantly, 
Fig. 1 Linagliptin (LGT) has neutral effects on body weight and aortic advanced glycation end‑products (AGE). a WD feeding for 4 months resulted 
in significant weight gain in both the cohorts. b Plasma DPP‑4 activity was significantly decreased with LGT treatment. c AGE immunostaining in 
aorta was significantly increased in WDC. LGT treatment did not decrease it significantly. Quantification and representative images shown. Values 
are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control, WDL western diet linagliptin. Post‑hoc comparisons 






























a   b
Fig. 2 LGT prevents development of in vivo aortic stiffening, as well 
as endothelial stiffening in ex vivo aortic explants. a Pulse wave veloc‑
ity (PWV) measured after 4 months on experimental diets. b Force 
measurements were acquired by interaction between a cantilever 
tip and the EC surface of aortic explants from mice after 4 months on 
WD. Values are mean ± SE. CDC control diet control, CDL control diet 
linagliptin, WDC western diet control and WDL western diet linaglip‑
tin. Post‑hoc comparisons within a time point; *p < 0.05 CDC vs WDC; 
†p < 0.05 WDC vs WDL
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DPP-4 Inhibition ameliorated aortic oxidative stress by 
normalization of 3-nitrotyrosine induced by WD feeding 
(Fig. 6).
DPP‑4 inhibition prevents WD‑induced changes in FGF‑23 
and Klotho expression in the vascular wall
FGF-23 is associated with arterial stiffness and increased 
risk of CVD [21–23]. We have recently shown that this 
WD feeding paradigm results in increased FGF23 in 
the vascular wall [24]. Furthermore, decreased Klotho 
expression, another protein involved in vascular calci-
fication, is known to exacerbate diet-induced vascular 
stiffness [9]. Herein we examined whether WD induces 
changes in FGF-23 and Klotho expression in the aorta, 
and if so, whether DPP-4 inhibition prevented that 
change (Fig.  7). As anticipated, we observed a signifi-
cant increase in FGF-23 in the aortic endothelium and 
adventitia of the WDC group compared with CDC, and 
this increase was prevented in the WDL group (Fig. 7a–
c). In addition, Klotho expression was significantly 
decreased by WD feeding and DPP-4 inhibition pre-
vented this deficiency in the vascular wall (Fig. 7d–g).
Discussion
Collectively, the results of this investigation support the 
hypothesis that DPP-4 activation plays an important 
role in the development of aortic stiffness in female mice 
in the setting of WD-induced insulin resistance. Fur-
thermore, we present evidence that DPP-4 inhibition 
prevented female C57BL/6 J mice from developing WD-
induced aorta stiffening, remodeling and dysfunction. We 
previously reported that WD feeding for 4 months does 
not increase blood pressure in female C57BL/6J [9]. This 
previous finding enabled us to design an experiment that 
Table 1 Aortic stiffness in untreated western diet (WD)-fed mice compared to untreated control diet (CD) fed mice as indi-
cated by determinations of aortic pulse wave velocity (PWV)
Also shown, is heart rate (HR) and PWV normalized to HR. Administration of linagliptin (WDL) prevented the increase in PWV observed WD-fed mice (WDC). Sample 
sizes are noted in parentheses. Values are mean ± SE
CDC control diet control, CDL control diet linagliptin, WDC western diet control and WDL western diet linagliptin. Post-hoc comparisons
* p < 0.05 CDC vs WDC; † p < 0.05 WDC vs WDL
Pulse wave velocity Main effect p value CDC [6] CDL [8] WDC [10] WDL [10]
4 months PWV (m s−1) Diet 0.001 3.31 ± 0.08 3.28 ± 0.07 4.11*† ± 0.16 3.44 ± 0.11
Treatment 0.001
Interaction 0.017
Heart rate (bpm) Diet 0.036 442 ± 22 439 ± 26 397* ± 12 415 ± 5
Treatment 0.639
Interaction 0.496
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Fig. 3 Vasodilator responses of isolated aortic rings to the endothelium‑dependent dilators acetylcholine (a) and insulin (b). Values are mean ± SE. 
CDC control diet control, CDL control diet linagliptin, WDC western diet control and WDL western diet linagliptin. Post‑hoc comparisons within a 
time point; *p < 0.05 CDC vs WDC; †p < 0.05 WDC vs WDL
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factored out a potential blood pressure effect to explain 
the CV protective effects of DPP-4 inhibition.
Beneficial vascular effects of DPP-4 inhibition have 
been attributed to both direct effects of DPP-4 inhibition 
and to the collateral increase in glucagon like peptide-1 
(GLP-1) availability [10]. In the vessel, DPP-4 is located 
in the cytoplasmic membrane of both EC and vascular 
smooth muscle cells (VSMC). In EC, DPP-4 expression 
is increased in models of diabetes [25] and in VSMC, 
DPP-4 expression is preferentially increased in condi-
tions of vascular remodeling [11]. Importantly, the dose 
of LGT used in our investigation significantly inhibits 
DPP-4 activity [12, 14, 26].
Our group previously showed that 4  months of WD 
feeding in female mice resulted in increases in aortic 
stiffness, measured non-invasively, as well as EC stiff-
ness, measured ex vivo [9]. Results of this study using a 
separate cohort of mice were nearly identical with our 
previous report and further demonstrate aortic and EC 
stiffening after 4 months of WD feeding. Notably, DPP-4 
inhibition prevented the development of aortic stiffness, 
both in vivo and ex vivo, observed in untreated WD-fed 
mice. Although previous reports demonstrate that DPP-4 
inhibitors decrease cardiac stiffness [12, 27, 28], to the 
best of our knowledge this is the first report demonstrat-
ing protection from vascular stiffening in a clinically rel-
evant non-diabetic female model of over-nutrition.
Vascular stiffness is determined by EC and VSMC 
properties, as well as by extracellular matrix and adven-
titial characteristics [7]. In our experiments, DPP-4 
inhibition in the WD-fed cohort prevented the develop-
ment of impaired endothelial-dependent vasodilation, 
an effect in the aorta that is known to be largely NO-
dependent [29, 30]. In this regard, DPP-4 inhibitors exert 
direct effects on vascular tone independently of GLP-1 
[11]. The DPP-4 inhibitors, LGT and alogliptin, in par-
ticular, exert vasodilatory effects in the aorta in the set-
ting of enhanced inflammation and oxidative stress and 
these effects were mediated by the NO/cGMP pathway 
[14]. We previously reported a similar improvement in 
endothelium-dependent vasodilation in skeletal muscle 
arterioles with LGT administration in a model of obesity 
and insulin resistance [12]. More recently we showed that 
impaired NO signaling accompanies increased vascular 
oxidative stress in our WD-fed mouse model [9]. Thus, 
it is likely that a decrease in oxidative stress in our WD-
fed female mice administered a DPP-4 inhibitor, helped 
to preserve normal aortic vaso-relaxation by preventing 
NO scavenging by free radicals, such as superoxide, as 
evidenced by a decrease in 3-nitrotyrosine staining in the 
aorta compared to untreated mice [7, 31]. In a different 
model of obesity and insulin resistance, LGT also ame-
liorated oxidative stress associated with cerebral ischemia 
independently of glycemic control [32], findings that 
Fig. 4 WD feeding causes a, b peri‑aortic fibrosis and (c, d) medial thickening which is ameliorated by the DPP‑4 inhibitor, LGT. a Picro sirius red 
and b Verhoeff‑von Gieson staining. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control and WDL 
western diet linagliptin. Post‑hoc comparisons within a time point; *p < 0.05 CDC vs WDC; †p < 0.05 WDC vs WDL
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Fig. 5 LGT treatment ameliorates loss of luminal EC cytoplasmic elongation and nuclear contraction induced by WD. a, b depict CDC and CDL 
cohorts with normal EC characteristics; c depicts contracted cytoplasm and nuclei of EC in WDC; d demonstrates the absence of luminal EC swell‑
ing, edema and contracted cytoplasm and nuclei seen in c. Magnification ×800; bar 2 µm. EL elastic lamina, IEL internal elastic lamina, N nucleus of 
luminal endothelial cell, VSMC vascular smooth muscle cell
Fig. 6 WD feeding induced aortic oxidative stress is ameliorated with DPP‑4 inhibition. a 3‑nitrotyrosine staining; b EC 3‑nitrotyrosine; c VSMC 
3‑nitrotyrosine. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control and WDL western diet lina‑
gliptin. Post‑hoc comparisons within a time point; *p < 0 0.05 CDC vs WDC; †p < 0.05 WDC vs WDL
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further support the concept that the antioxidant proper-
ties of LGT may be vasculoprotective.
Likewise, the beneficial role of DPP-4 inhibition in 
restoring endothelial-dependent vasodilation in condi-
tions of increased oxidative stress has been documented 
in other murine models [33, 34]. It should be noted that 
even though the magnitude of the aortic vasodilatory 
responses reported in this investigation seem low, similar 
results in mice have been reported from other laborato-
ries [35–37]. Furthermore, our ultra-structural findings 
suggest that DPP-4 inhibition reverses the loss of lumi-
nal endothelial cytoplasmic elongations and nuclear con-
traction associated with WD feeding. Additionally, our 
findings indicate that the beneficial effects of the DPP-4 
inhibition are not limited to the endothelium. Here, we 
observed that DPP-4 inhibition decreases medial thick-
ening and fibrosis related to WD-feeding. The vascular 
anti-fibrotic role of DPP-4 inhibitors has been reported 
previously in models of atherosclerosis and neo-intima 
injury [34, 38].
FGF-23 is elevated in conditions of insulin resistance 
and obesity [39, 40]. Importantly, FGF-23 levels are asso-
ciated with impaired vascular relaxation, vascular calci-
fication and stiffness [22, 40, 41]. Moreover, FGF-23 is 
expressed in the vasculature [42] and has been shown to 
enhance oxidative stress and induce inhibition of NO-
dependent vasodilation [43]. We recently reported that 
female WD-fed mice exhibit increased FGF-23 levels 
and this was associated with impaired aortic endothelial 
function, increased aortic PWV and increased oxidative 
stress [24]. FGF-23 effects may be modulated, in part, via 
Klotho [44]. In this regard, Klotho deficiency was recently 
reported to accelerate aortic stiffening in high fat fed 
mice [45]. Whether WD leads to a deficiency in Klotho 
expression has not been examined previously. Herein, we 
explored a possible contribution of FGF-23 and Klotho 
to the genesis of vascular stiffening, endothelial dysfunc-
tion and oxidative stress by testing whether DPP-4 inhi-
bition prevents the increase in aortic FGF-23 expression 
and modulates Klotho expression in the aorta of WD-
fed mouse model. In the present work, FGF-23 expres-
sion was increased in the aorta of WD-fed mice and this 
was prevented with DPP-4 inhibition. Furthermore, the 
expression of Klotho was decreased in the aorta of WD-
fed mice relative to control mice and this deficiency was 
prevented with administration of LGT. In this regard and 
relevant to our findings, others have reported that Klotho 
deficiency results in increased production of reactive 
oxygen [46], while its over-expression ameliorates oxida-
tive stress [47]. Since oxidative stress has been implicated 
in the impairment of vascular relaxation and bioavailable 
NO, the prevention of abnormal expression of FGF23 
and Klotho by DPP-4 inhibition in the vasculature may 
represent a new mechanism to explain the efficacy of 
DPP-4 inhibition in preventing the appearance of vas-
cular stiffness. Whether FGF-23/Klotho signaling in the 
Fig. 7 WD feeding induced changes in FGF‑23 and Klotho expression are restored by DPP‑4 inhibition. a FGF‑23 staining; b Endothelial FGF‑23;  
c Adventitia FGF‑23; d Endothelial klotho staining; e Endothelial klotho staining f Adventitia klotho staining; Average gray intensities in the different 
cohorts. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control and WDL western diet linagliptin. 
Post‑hoc comparisons within a time point; *p < 0 0.05 CDC vs WDC; †p < 0.05 WDC vs WDL; #p < 0.05 CDC vs CDL. Scale bars represent 50 mμ
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vasculature, in concert with its vascular receptors and 
cofactors, directly modulates vascular function or influ-
ences vascular function via regulation of putative effects 
on mineral metabolism is unclear.
In the present investigation we did not observe that 
LGT prevented or reduced WD-induced weight gain 
suggesting that the efficacy of LGT in preventing WD-
induced aortic stiffening, impaired vasoreactivity and 
abnormal remodeling did not result from beneficial 
weight loss. Some rodent studies have documented a 
similar neutral effect of LGT administration on body 
weight in association with improvement in cardio-
vascular function and structure [25, 48]. On the other 
hand, higher doses of LGT led to modest weight loss in 
rats fed a high fat diet [49]. Importantly clinical trials 
have supported the notion of weight stability with LGT 
treatment [50–52]. One of the limitations of the present 
investigation is that we did not directly evaluate glu-
cose homeostasis or insulin resistance. Nevertheless, we 
have previously demonstrated that this diet paradigm in 
female C57BL/6J mice does not result in frank hypergly-
cemia while it manifests significant whole body insulin 
resistance evaluated by the hyperinsulinemic euglycemic 
clamp [53]. Herein, we further explored the possibility 
that DPP-4 inhibition reduces the anticipated increase in 
expression of AGE products as AGE/RAGE signaling can 
result in a pro-inflammatory and pro-oxidant environ-
ment [54]. Furthermore, AGE can increase expression of 
DPP-4 in EC [55]. In the present investigation, we docu-
mented increased AGE presence in the vascular wall of 
WD-fed females, and this was not prevented with DPP-4 
inhibition. This suggests that the efficacy of DPP-4 inhi-
bition in the vasculature of WD-fed female mice occurs 
without significant changes in AGE. To the best of our 
knowledge this is the only study demonstrating that a 
DPP-4 inhibitor prevents development of diet-induced 
vascular stiffness. Further studies are needed to clarify if 
other DPP-4 inhibitors share these beneficial effects.
Despite abundant preclinical evidence of cardiovas-
cular benefits of DPP-4 inhibitors, including results 
presented herein, meta-analyses of clinical data raise con-
cerns regarding evidence of increased risk of heart fail-
ure with administration of certain DPP-4 inhibitors [56]. 
On the other hand, other recent analyses have produced 
differing conclusions regarding heart failure risk assess-
ment [57]. In the SAVOR-TIMI 53 trial the use of saxa-
gliptin was associated with increased risk of heart failure 
[58]. Importantly, the risk was higher in the subjects with 
previous heart failure, elevated natriuretic peptides and 
impaired renal function [59]. In the EXAMINE trial that 
explored the use of alogliptin in type 2 diabetics with 
post-acute coronary events there was no increased risk 
of major CV events [60]. Nevertheless, a recent post hoc 
analysis of the EXAMINE trial did find a statistically sig-
nificant increase in hospitalization rate from heart failure 
in the group of subjects without heart failure history [61]. 
On the contrary, the sitagliptin TECOS trial did not find 
differences in the rate of hospitalization for heart failure 
between the treatment and the control group [62]. Simi-
larly, a recent pre-specified patient-level pooled analysis 
of available trials of LGT did not report an association 
between the DPP-4 inhibitor and increased CV risk 
(including heart failure) [63]. Results from two ongoing 
trials using LGT, the CAROLINA (NCT01243424) and 
CARMELINA (NCT01897532), will further clarify the 
role and safety of this agent in regard to diabetic CVD.
To summarize, the current investigation demonstrates 
that DPP-4 inhibition prevents abnormal increases 
in vascular stiffness, aortic fibrosis, oxidative stress 
and FGF-23/Klotho expression induced by a WD in 
female mice and these benefits occur independent of 
AGE reduction. Our findings have clinical relevance as 
obese diabetic women are more frequently affected by 
increased vascular stiffness that likely promotes higher 
incident CVD compared to their male counterparts. Ulti-
mately, only the results of well-designed clinical trials will 
clarify the role of LGT in the management of diabetic 
CVD.
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